Literature DB >> 32652059

Positional Isomers of a Non-Nucleoside Substrate Differentially Affect Myosin Function.

Mike Woodward1, Eric Ostrander2, Seung P Jeong2, Xiarong Liu3, Brent Scott1, Matt Unger1, Jianhan Chen3, Dhandapani Venkataraman2, Edward P Debold4.   

Abstract

Molecular motors have evolved to transduce chemical energy from ATP into mechanical work to drive essential cellular processes, from muscle contraction to vesicular transport. Dysfunction of these motors is a root cause of many pathologies necessitating the need for intrinsic control over molecular motor function. Herein, we demonstrate that positional isomerism can be used as a simple and powerful tool to control the molecular motor of muscle, myosin. Using three isomers of a synthetic non-nucleoside triphosphate, we demonstrate that myosin's force- and motion-generating capacity can be dramatically altered at both the ensemble and single-molecule levels. By correlating our experimental results with computation, we show that each isomer exerts intrinsic control by affecting distinct steps in myosin's mechanochemical cycle. Our studies demonstrate that subtle variations in the structure of an abiotic energy source can be used to control the force and motility of myosin without altering myosin's structure.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32652059      PMCID: PMC7401181          DOI: 10.1016/j.bpj.2020.06.024

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  63 in total

1.  What limits the velocity of fast-skeletal muscle contraction in mammals?

Authors:  Miklós Nyitrai; Rosetta Rossi; Nancy Adamek; Maria Antonietta Pellegrino; Roberto Bottinelli; Michael A Geeves
Journal:  J Mol Biol       Date:  2005-11-09       Impact factor: 5.469

Review 2.  Sliding filaments and molecular motile systems.

Authors:  H E Huxley
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

3.  Smooth and skeletal muscle myosin both exhibit low duty cycles at zero load in vitro.

Authors:  D E Harris; D M Warshaw
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

4.  Preparation of myosin and its subfragments from rabbit skeletal muscle.

Authors:  S S Margossian; S Lowey
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

5.  The effects of phosphate and acidosis on regulated thin-filament velocity in an in vitro motility assay.

Authors:  Edward P Debold; Thomas J Longyear; Matthew A Turner
Journal:  J Appl Physiol (1985)       Date:  2012-09-27

6.  Driving and photo-regulation of myosin-actin motors at molecular and macroscopic levels by photo-responsive high energy molecules.

Authors:  Halley M Menezes; Md Jahirul Islam; Masayuki Takahashi; Nobuyuki Tamaoki
Journal:  Org Biomol Chem       Date:  2017-10-31       Impact factor: 3.876

7.  CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.

Authors:  K Vanommeslaeghe; E Hatcher; C Acharya; S Kundu; S Zhong; J Shim; E Darian; O Guvench; P Lopes; I Vorobyov; A D Mackerell
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

8.  Acting on actin: the electric motility assay.

Authors:  D Riveline; A Ott; F Jülicher; D A Winkelmann; O Cardoso; J J Lacapère; S Magnúsdóttir; J L Viovy; L Gorre-Talini; J Prost
Journal:  Eur Biophys J       Date:  1998       Impact factor: 1.733

9.  X-ray structure of the magnesium(II).ADP.vanadate complex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution.

Authors:  C A Smith; I Rayment
Journal:  Biochemistry       Date:  1996-04-30       Impact factor: 3.162

10.  Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure.

Authors:  Shin Kadota; John Carey; Hans Reinecke; James Leggett; Sam Teichman; Michael A Laflamme; Charles E Murry; Michael Regnier; Gregory G Mahairas
Journal:  Eur J Heart Fail       Date:  2015-04-15       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.